1. Home
  2. WRN vs NBTX Comparison

WRN vs NBTX Comparison

Compare WRN & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Copper and Gold Corporation

WRN

Western Copper and Gold Corporation

HOLD

Current Price

$2.68

Market Cap

452.6M

ML Signal

HOLD

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

HOLD

Current Price

$22.40

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WRN
NBTX
Founded
2006
2003
Country
Canada
France
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
452.6M
1.0B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
WRN
NBTX
Price
$2.68
$22.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$4.13
$8.00
AVG Volume (30 Days)
994.3K
32.6K
Earning Date
03-24-2026
09-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$11,930,711.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$145.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$2.82
52 Week High
$3.02
$30.35

Technical Indicators

Market Signals
Indicator
WRN
NBTX
Relative Strength Index (RSI) 55.36 48.55
Support Level $2.65 $21.67
Resistance Level $3.02 $23.40
Average True Range (ATR) 0.13 0.93
MACD -0.02 -0.09
Stochastic Oscillator 36.10 8.95

Price Performance

Historical Comparison
WRN
NBTX

About WRN Western Copper and Gold Corporation

Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).

About NBTX Nanobiotix S.A.

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Share on Social Networks: